Significance of operative parameters on outcomes after transurethral resection of the prostate

Milonas, Daimantas

doi:10.3390/medicina46010004

Cited by 5 publications

(4 citation statements)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 However, it has been frequently reported that patients with BPH suffered from LUTS, stress, anxiety, depression, and incapacity to complete basic tasks due to the psychological impacts. [17][18][19][20] Previous studies on BPH patients who undergoing TURP only emphasized the examination of postoperative comorbidities or the technical success of the operation, whereas seldom paid attention to the correlations between TURP treatments for BPH and the adverse psychological effects.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Risk Factors of Post-Operative Depression in Patients Undergoing Transurethral Resection of Prostate for Benign Prostatic Hyperplasia

Zhu

Gao

Dou

et al. 2021

IJGM

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Incidence and Risk Factors of Post-Operative Depression in Patients Undergoing Transurethral Resection of Prostate for Benign Prostatic Hyperplasia

Zhu

Gao

Dou

et al. 2021

IJGM

View full text Add to dashboard Cite

“…The biggest challenge in the present study was to estimate model inputs, due to lack of local data in published literature. Clinical data were based on the pivotal trial (the ComBAT study), incidence, prevalence of BPH and LUTS [ 29 ] data were extracted from European sources [ 22 , 23 ], and were subsequently confirmed by the expert panel. Our analysis was performed with inclusion of all patients, regardless of pre-treatment prostate volume (326,000 men estimation).…”

Section: Discussionmentioning

confidence: 99%

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting

Geitona

Karabela²,

Katsoulis³

et al. 2014

BMC Urol

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to explore the budget impact of dutasteride plus tamsulosin fixed-dose combination (DUT + TAM FDC) versus tamsulosin monotherapy, in the treatment of patients with benign prostatic hyperplasia (BPH) from the perspective of the Greek healthcare insurance system.MethodsA Microsoft Excel-based model was developed to estimate the financial consequences of adopting DUT + TAM FDC within the Greek healthcare setting. The model, compared six mutually exclusive health states in two alternative treatment options: current standard of care and the introduction of DUT + TAM FDC in the market. The model used clinical inputs from the CombAT study; data on resource use associated with the management of BPH in Greece were derived from expert panel, and unit cost data were derived from official reimbursement tariffs. A payer perspective was taken into account. As patient distribution data between public and private sectors are not available in Greece two scenarios were investigated, considering the whole eligible population in each scenario. A 4 year time horizon was taken into account and included treatment costs, number of transurethral resections of the prostate (TURPs) and acute urinary retention (AUR) episodes avoided.ResultsThe clinical benefit from the market adoption of DUT + TAM FDC in Greece was 1,758 TURPs and 972 episodes of AUR avoided cumulatively in a four year period. The increase in total costs from the gradual introduction of DUT + TAM FDC to the Greek healthcare system ranges from €1.3 million in the first year to €5.8 million in the fourth year, for the public sector, and €1.2 million to €4.0 million, for the private sector. This represents an increase of 1.91% to 7.94% for the public sector and 1.10% 3.29% in the private sector, during the 4-year time horizon.ConclusionsBudget impact analysis (BIA) results indicated that the gradual introduction of DUT + TAM FDC, would increase the overall budget of the disease, however providing better clinical outcomes. DUT + TAM FDC drug acquisition cost is partly offset by the reduction in the costs associated with the treatment of the disease.

show abstract

“…Transurethral resection of the prostate (TURP) is an effective treatment modality for lower urinary tract symptoms (LUTS) secondary to a benign obstruction of the prostate (BOP) [ 1 ]. However, in some patients, the improvement of symptoms after TURP is insufficient [ 2 , 3 ]. Therefore, studies have been conducted to detect parameters that can predict outcomes after the intervention.…”

Section: Introductionmentioning

confidence: 99%

The effect of complete transurethral resection of the prostate on symptoms, quality of life, and voiding function improvement

Milonas¹,

Verikaitė²,

Jievaltas³

2015

CEJU

Self Cite

View full text Add to dashboard Cite

IntroductionTransurethral resection of the prostate (TURP) still remains the most popular surgical treatment for patients with lower urinary tract symptoms. However, in some patients, the improvement of symptoms after TURP is insufficient. The aim of our study was to evaluate the impact of the resected prostate tissue weight (RPTW) on the improvement of symptoms (IPSS), quality of life (QoL), and voiding function after TURP.Material and methodsThe study included 89 men who had undergone TURP in our institution. IPSS, QoL, post–voiding residual urine volume (PVR) and Qmax were recorded before the operation and six months after TURP. The total prostate volume (TPV) and transition zone volume (TZV) were measured before the operation by transrectal ultrasound. The impact of RPTW, RPTW/TZV ratio, and RPTW/TPV ratio were analyzed according to the efficacy of TURP.ResultsThe mean Qmax after TURP increased by 10.15 mL/s, IPSS decreased by 16.7 points, QoL increased by 3.57 points, and PVR decreased by 95.3 mL. According to Qmax, the treatment was effective in 74.2%, according to IPSS, in 91%, and according to QoL, in 74.2% of patients. The ROC analysis demonstrated that RPTW/TZV and RPTW/TPV ratios were the most significant predictors of obtaining favorable results. Survival analysis (life table) shows that in order to achieve 50% improvement on Qmax, QoL, and IPSS, more than 30–35% of TPV and more than 60% of the TZV should be removed.ConclusionsThe efficacy of the TURP at short term follow-up depends on the completeness of the resection.

show abstract

Significance of operative parameters on outcomes after transurethral resection of the prostate

Cited by 5 publications

References 13 publications

Incidence and Risk Factors of Post-Operative Depression in Patients Undergoing Transurethral Resection of Prostate for Benign Prostatic Hyperplasia

Incidence and Risk Factors of Post-Operative Depression in Patients Undergoing Transurethral Resection of Prostate for Benign Prostatic Hyperplasia

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting

The effect of complete transurethral resection of the prostate on symptoms, quality of life, and voiding function improvement

Contact Info

Product

Resources

About